Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Lumosa Therapeutics Co. Ltd.
DescriptionLong-acting formulation containing a prodrug of nalbuphine, a mu opioid receptor (OPRM1; MOR) antagonist and kappa opioid receptor (OPRK1; KOR) agonist
Molecular Target Mu opioid receptor (MOR) (OPRM1) ; Kappa opioid receptor (KOR) (OPRK1)
Mechanism of ActionKappa opioid receptor agonist; Mu opioid receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II/III
Standard IndicationPain
Indication DetailsTreat moderate to severe pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today